Update on Psoriasis Therapy

The presentation discusses recent advancements in psoriasis therapies, particularly focusing on new drugs and their mechanisms of action. Bimikizumab, a monoclonal antibody that inhibits IL-17A and IL-17F, has shown rapid efficacy with 90% of patients achieving PASI 90 in studies, although it carries a higher risk of mucosal candidiasis than traditional IL-17 inhibitors. There's a flexible dosing schedule based on patient weight, with promising retention of efficacy over time. The efficacy comparison between risankizumab and apremilast indicates that risankizumab yields superior PASI outcomes, affecting patient preference for treatment. Additionally, spizolamab has been evaluated for generalized pustular psoriasis, showing effectiveness in reducing pustules significantly within a week following IV dosing. The presentation also highlights investigational treatments like TAC 279, a TIC2 inhibitor, which may outperform existing therapies, and an oral IL-23 receptor antagonist, currently in development, which shows promising efficacy in trial phases. Lastly, a unique study involving guselkumab in darker skin types emphasizes the psychosocial impact of skin disorders, revealing improvements in both skin condition and associated discoloration challenges, which underscores the importance of holistic patient care.